• Policy
• Detailed screening for α -GPC begins in earnest next year
• by Moon, sung-ho Dec 7, 2021 05:57am

• Policy
• The original patent's negotiation period will be reduced
• by Kim, Jung-Ju Dec 7, 2021 05:57am

• Company
• Five companies give up challenging Dukarb’s patent
• by Kim, Jin-Gu Dec 6, 2021 05:54am

• Product
• Losartan's re-prescription & re-dispensing are imminent
• by Jung, Heung-Jun Dec 6, 2021 05:54am

• Policy
• KB Pharm's generic for Vildagliptin nitrate will be approved
• by Lee, Tak-Sun Dec 6, 2021 05:54am

• Policy
• Asciminib's domestic approval is at a quick step
• by Lee, Tak-Sun Dec 6, 2021 05:53am

• Product
• Why Tagrisso and Opdivo failed reimbursement expansions
• by Moon, sung-ho Dec 6, 2021 05:53am

• Policy
• Companies in a dilemma over who bears losartan recall cost
• by Lee, Tak-Sun Dec 3, 2021 05:55am

• Company
• Moderna Korea appoints Ji-Young Sohn as new GM
• by Dec 3, 2021 05:55am

• Company
• COVID-19 vaccinations freeze up the premium vaccine market
• by Chon, Seung-Hyun Dec 2, 2021 05:54am